These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27251583)

  • 1. Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations.
    Repplinger DJ; Hoffman RS; Nelson LS; Hines EQ; Howland M; Su MK
    Clin Toxicol (Phila); 2016 Sep; 54(8):647-9. PubMed ID: 27251583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: A case report.
    Pfeiffer H; Herbst L; Schwarze B; Eckstein R; Weisbach V
    Medicine (Baltimore); 2016 Nov; 95(44):e5343. PubMed ID: 27858919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.
    Kim B; Jang S; Lee YJ; Park N; Cho YU; Park CJ
    J Thromb Thrombolysis; 2020 Feb; 49(2):245-250. PubMed ID: 31506888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery.
    Chic Acevedo C; Velasco F; Herrera C
    Future Cardiol; 2015 Sep; 11(5):525-9. PubMed ID: 26090568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
    Greenblatt DJ; Patel M; Harmatz JS; Nicholson WT; Rubino CM; Chow CR
    J Clin Pharmacol; 2018 Apr; 58(4):533-540. PubMed ID: 29194698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The X factor: Lack of bleeding after an acute apixaban overdose.
    Leikin SM; Patel H; Welker KL; Leikin JB
    Am J Emerg Med; 2017 May; 35(5):801.e5-801.e6. PubMed ID: 27884586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
    Weirthein J; Scolnik D; Milshtein NY; Capua T; Glatstein M
    Pediatr Emerg Care; 2019 Mar; 35(3):e44-e46. PubMed ID: 29337837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Xa activity in apixaban overdose: a case report.
    Barton J; Wong A; Graudins A
    Clin Toxicol (Phila); 2016 Nov; 54(9):871-873. PubMed ID: 27436437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
    Tellor KB; Patel S; Armbruster AL; Daly MW
    J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
    Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA;
    Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P; Ammirati F;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.